Audentes

Showing 1 posts of 1 posts found.

Astellas poised to acquire neuromuscular disease specialist Audentes for $3bn all-cash

December 3, 2019
Manufacturing and Production, Sales and Marketing Astellas, Audentes, acquisition, neuromuscular disease, pharma

Astellas Pharma is set to acquire US-based Audentes Therapeutics in an all-cash deal valued at $3 billion in cash, it …

The Gateway to Local Adoption Series

Latest content